Endometrial Cancer

"Sac-TMT may be able to address a critical unmet need for certain patients with advanced endometrial cancer," said Domenica Lorusso, MD, PhD.

Trastuzumab pamirtecan, a novel antibody-drug conjugate, showed initial efficacy signals in pretreated patients with HER2-expressing endometrial cancer.

Precision medicine revolutionizes endometrial cancer treatment, emphasizing molecular drivers and the challenges of next-generation sequencing in clinical decision-making.

A groundbreaking trial reveals the promising efficacy of fruquintinib and sintilimab for advanced endometrial cancer, offering new hope for patients.

Novel small molecule inhibitors show promising efficacy in endometrial cancer, with ongoing trials expanding treatment options for challenging patient populations.

AstraZeneca and Daiichi Sankyo launch a pivotal trial to assess T-DXd as a potential adjuvant therapy for HER2-expressing endometrial cancer.

The FDA approves a new diagnostic tool enhancing precision treatment for advanced endometrial carcinoma, improving patient outcomes with targeted therapies.

The Wee1 inhibitor adavosertib shows activity in recurrent uterine serous carcinoma, but the drug’s tolerability remains a challenge.

A retrospective study showed that either folate receptor alpha or B7-H4 was expressed in more than 80% of endometrial cancers evaluated.

The phase 2/3 GOG286B reported efficacy findings and new exploratory outcomes on the combination of metformin, paclictaxel, and carboplatin in patients with advanced or recurrent endometrial cancer.

Dual checkpoint inhibitors led to longer overall survival in patients with high-risk endometrial cancer who displayed inactivating PPP2R1A mutations vs patients with wild-type PPP2R1A.

Alexander J. Fife, MD, discussed the challenges of diagnosing endometrial cancer, highlighting delays in care.

During a Case-Based Roundtable® event, Michael J. Birrer, MD, PhD, moderated a discussion on what factors affect the need for testing and treatment changes in patients with recurrent endometrial carcinoma.

The combination of lenvatinib and pembrolizumab showed promising results in treating recurrent endometrial carcinoma, demonstrating significant antitumor activity and improved survival rates compared to standard therapy.

While the phase 3 ENGOT-en11/GOG-3053/KEYNOTE-B21 trial missed its end point of disease-free survival, benefits were still observed in the dMMR subgroup.

Dostarlimab plus chemotherapy has been approved for the treatment of all forms of advanced endometrial cancer, including mismatch repair-deficient and microsatellite stable tumors.